Create Account | Sign In: Author or Forum

Search Symptoms

Category: Cardiology | Dermatology | Endocrinology | Family Medicine | Geriatrics | Gastroenterology | Gynecology | Infections | AIDS | Internal Medicine | Allergy | Nephrology | Neurology | Oncology | Ophthalmology | Orthopedics | ENT | Pharmacy | Psychiatry | Pulmonology | Rheumatology | Urology | Institutional

Back to Journal Articles

Bipartisan Bill to Curb Drug Costs Backed by White House

Last Updated: November 18, 2019.

A bipartisan Senate bill that would curb prescription drug costs is being backed by the Trump administration as a new poll shows that many Americans think the White House has done little to tackle the issue.

MONDAY, Nov. 18, 2019 (HealthDay News) -- A bipartisan Senate bill that would curb prescription drug costs is being backed by the Trump administration as a new poll shows that many Americans think the White House has done little to tackle the issue.

The Gallup-West Health poll found that 66 percent of adults do not believe the Trump administration has made any or very much progress in curbing the rising cost of prescription drugs, the Associated Press reported.

The Senate bill does not give Medicare bargaining power but would cap out-of-pocket payments by Medicare beneficiaries and make drug makers pay rebates if they raise prices too high, the AP reported.

There is also a competing House Democratic bill, which would build on the Senate bill by also authorizing Medicare to negotiate prices for the costliest drugs. Along with curbing price increases, the House bill would limit high launch prices for new drugs, and privately insured people would also be eligible for Medicare discounts, the AP reported.

AP News Article


Previous: White House Wants Hospitals, Insurers to Provide Actual Costs of Care Next: AHA: Lower-Target LDL Level Beneficial After Stroke, TIA

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion: